Azenta (AZTA) Q2 Earnings Report Preview: What To Look For

Life sciences company Azenta (NASDAQ:AZTA) will be reporting results this Tuesday before the bell. Here’s what to look for.

Azenta beat analysts’ revenue expectations by 2% last quarter, reporting revenues of $143.4 million, up 5.2% year on year. It was a slower quarter for the company, with a significant miss of analysts’ EPS estimates.

Is Azenta a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Azenta’s revenue to grow 3.7% year on year to $149.6 million, a reversal from the 13% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.14 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Azenta has missed Wall Street’s revenue estimates four times over the last two years.

Looking at Azenta’s peers in the drug development inputs & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. West Pharmaceutical Services delivered year-on-year revenue growth of 9.2%, beating analysts’ expectations by 5.6%, and Medpace reported revenues up 14.2%, topping estimates by 11.3%. West Pharmaceutical Services traded up 15.9% following the results while Medpace was also up 54.6%.

Read our full analysis of West Pharmaceutical Services’s results here and Medpace’s results here.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the drug development inputs & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Azenta is up 1.6% during the same time and is heading into earnings with an average analyst price target of $34 (compared to the current share price of $31.94).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.